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e 13, 2013.he aim of this study was to test the effects of treatment with ivabradine on exercise capacity and left ventricular
ﬁlling in patients with heart failure with preserved ejection fraction (HFpEF).Background Because symptoms of HFpEF are typically exertional, optimization of diastolic ﬁlling time by controlling heart rate
may delay the onset of symptoms.Methods Sixty-one patients with HFpEF were randomly assigned to ivabradine 5 mg twice daily (n ¼ 30) or placebo (n ¼ 31)
for 7 days in this double-blind trial. Cardiopulmonary exercise testing with echocardiographic assessment of
myocardial function and left ventricular ﬁlling were undertaken at rest and after exercise.Results The ivabradine group demonstrated signiﬁcant improvement between baseline and follow-up exercise capacity
(4.2  1.8 METs vs. 5.7  1.9 METs, p ¼ 0.001) and peak oxygen uptake (14.0  6.1 ml/min/kg vs. 17.0  3.3
ml/min/kg, p ¼ 0.001), with simultaneous reduction in exercise-induced increase in the ratio of peak early diastolic
mitral ﬂow velocity to peak early diastolic mitral annular velocity (3.1  2.7 vs. 1.3  2.0, p ¼ 0.004). Work load–
corrected chronotropic response (the difference in heart rate at the same exercise time at the baseline and follow-up
tests) showed a slower increase in heart rate during exercise than in the placebo-treated group. Therapy with
ivabradine (b ¼ 0.34, p ¼ 0.04) and change with treatment in exertional increase in the ratio of peak early diastolic
mitral ﬂow velocity to peak early diastolic mitral annular velocity (b¼ 0.30, p ¼ 0.02) were independent correlates
of increase in exercise capacity, and therapy with ivabradine (b ¼ 0.32, p ¼ 0.007) was independently correlated
with increase in peak oxygen uptake.Conclusions In patients with HFpEF, short-term treatment with ivabradine increased exercise capacity, with a contribution from
improved left ventricular ﬁlling pressure response to exercise as reﬂected by the ratio of peak early diastolic mitral
ﬂow velocity to peak early diastolic mitral annular velocity. Because this patient population is symptomatic on
exertion, therapeutic treatments targeting abnormal exercise hemodynamic status may prove useful. (Use of
Exercise and Medical Therapies to Improve Cardiac Function Among Patients With Exertional Shortness of Breath
Due to Lung Congestion; ACTRN12610001087044) (J Am Coll Cardiol 2013;62:1330–8) ª 2013 by the
American College of Cardiology FoundationPatients with heart failure with preserved ejection fraction
(HFpEF) are characterized by symptoms of dyspnea and
exercise intolerance, both of which contribute to reduced
quality of life in this population. This is a major health care
problem, accounting for almost one-half of all cases of
chronic cardiac insufﬁciency in large-scale community studies
(1,2). Current therapeutic recommendations are to effectivelyity, Wroclaw, Poland; yUniversity of Queens-
enzies Research Institute Tasmania, Hobart,
that they have no relationships relevant to the
3; revised manuscript received May 22, 2013,control the comorbidities associated with HFpEF, especially
hypertension, diabetes, coronary artery disease, and obesity (3).
However, there is a clear need for the development of new
strategies beyond the management of underlying etiologies.
See page 1339
The latest heart failure guidelines have extended the
treatment possibilities for heart failure with reduced left
ventricular (LV) ejection fraction by incorporating ivabra-
dine, a selective sinus node inward “funny” (If) channel
inhibitor reducing heart rate, devoid of negative inotropic
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1331effect, which was shown to decrease mortality and morbidity
in the Systolic Heart Failure Treatment With the If In-
hibitor Ivabradine Trial (4,5). In the early stages of HFpEF,
while the primary problem relates to impaired LV relaxation
(rather than impaired LV compliance or increased ﬁlling
pressure at rest), high heart rates during exercise may be
particularly detrimental by reducing time for diastolic ﬁlling
and promoting increased LV ﬁlling pressure and exercise
intolerance. Therapeutic measures prolonging the LV ﬁlling
phase may optimize transmitral ﬂow, thereby reducing
increased ﬁlling pressures and the resultant dyspnea. Although
beta-adrenoceptor blockade has been trialed in HFpEF, these
agents’ negative inotropic effect is disadvantageous. Thus, the
use of ivabradine in this group of patients with heart failure
might represent a novel opportunity to control exertion-
associated tachycardia without a deleterious impact on
myocardial contractility. This application of ivabradine is
consistent with the results of previous experimental studies that
have demonstrated improvements of myocardial diastolic
properties by If blockade (6–10). Accordingly, the aim of this
study was to investigate the effects of treatment with ivabradine
on exercise capacity and LV function, particularly the LV
ﬁlling pressure response to exercise, in patients with HFpEF.Methods
Study design. The present study was designed as a prospec-
tive, blinded, parallel-group, placebo-controlled trial evaluating
the potential of 7 days of therapy with ivabradine 5 mg twice
daily to improve exercise tolerance andLV function, especially
LV ﬁlling, with exercise in patients with HFpEF. This
report follows the recommendations of the 2010 Con-
solidated Standards of Reporting Trials statement (11). The
study adhered to the Declaration of Helsinki and was
approved by the institutional ethics committees. Informed
consent was obtained from all subjects before involvement in
the study.
Patient selection. Current guidelines endorsed by the
European Society of Cardiology were used to identify patients
with true HFpEF from 2 large hospital-based echocardiog-
raphy laboratories (University Hospital in Wroclaw, Poland,
and Princess Alexandra Hospital in Brisbane, Australia) (12).
In brief, patients presenting with signs or symptoms of heart
failure (i.e., dyspnea, fatigue, and exercise intolerance) with
normal systolic function as determined by LV ejection fr-
action 50% and evidence of diastolic dysfunction were
deemed suitable for screening. The diagnosis of LV diastolic
dysfunction was established according to the recommenda-
tions of the American Society of Echocardiography and the
European Association of Echocardiography (13). To enhance
the speciﬁcity of the association between diastolic abnormal-
ities and impaired functional capacity (14,15), the key criteria
essential for patient enrollment were exercise capacity <80%
of age-predicted and sex-predicted normal ranges and a ratio
of peak early diastolic mitral ﬂow velocity (E) to peak early
diastolic mitral annular velocity (e0) >13 after exercise,reﬂecting an increase in LV ﬁlling
pressure during exertion, both
evidenced from an exercise test.
From December 2011 to
December 2012, of 114 patients
meeting the criteria for diastolic
dysfunction, we ﬁnally recruited
61 patients of Caucasian race who
met the exercise capacity and E/e0
ratio criteria and were categorized
in New York Heart Association
functional class II or III (Fig. 1).
Of the 50 patients who were not
enrolled, 21 did not show signif-
icant reductions (<80% of normal
ranges) in exercise capacity, and
38 did not show exertional E/e0
ratios >13.
Exclusion criteria were an
absence of stable sinus rhythm;
ischemic heart disease (excluded
on the basis of the absence of
signiﬁcant atherosclerotic lesions
on coronary angiography and no evidence of inducible
ischemia during exercise testing); moderate and severe
valvular heart disease; heart rate <60 beats/min; sick sinus
syndrome; second-degree and third-degree atrioventricular
block; severe obesity (body mass index >36 kg/m2); estab-
lished or suspected pulmonary diseases (vital capacity <80%
or forced expiratory volume in 1 second <80% of age-
speciﬁc and sex-speciﬁc reference values); hemoglobin 11
g/dl; and treatment with nondihydropyridine calcium-
channel blockers, class I antiarrhythmic agents, strong
inhibitors of cytochrome P450 3A4, and QT interval–pro-
longing medications.
Study protocol. The baseline evaluation comprised physical
examination, cardiopulmonary exercise testing, resting and
immediate post-exercise echocardiography, and blood sam-
pling for laboratory measurements, including brain natri-
uretic peptide (BNP).
The procedure of randomization to receive either ivab-
radine 5 mg or placebo twice daily was performed by com-
puterized sequence generation. The hospital pharmacies
were responsible for drug randomization and dispensing,
and both the investigators and patients were blinded to
the treatment option. To check for the presence of br-
adycardia, patients were seen on the second and fourth days
after the initiation of treatment. In case of a resting heart
rate <50 beats/min or the occurrence of signs or symptoms
related to bradycardia, the dose of ivabradine was to be
reduced to 2.5 mg twice daily, or if these persisted after dose
reduction, the study medication was to be withdrawn.
After 7 days, the baseline investigations were repeated.
Echocardiography. Echocardiographic imaging was perf-
ormed using Vivid E9 and Vivid 7 equipment (GE Vi-
ngmed Ultrasound AS, Horten, Norway) with phased-array
Figure 1 Study Flow Diagram
Kosmala et al. JACC Vol. 62, No. 15, 2013
Ivabradine and Exercise Capacity in HFpEF October 8, 2013:1330–8
13322.5-MHz multifrequency transducers. All patients under-
went screening echocardiography to determine their suit-
ability for the trial by the evaluation of strict criteria for
HFpEF. The same imaging protocol was used at each visit
and performed by the same sonographer. Images were saved
in digital format and stored on a secure server for ofﬂine
analysis. The measurements of cardiac dimensions and wall
thicknesses and left atrial volume (area-length method) were
performed according to standard recommendations (16). LV
ejection fraction was determined using a modiﬁed Simpson
biplane method.
Peak E and late diastolic mitral ﬂow velocity (A) and the
deceleration time of the early diastolic ﬂow wave were assessed
from the apical 4-chamber view by pulsed-wave Doppler with
the sample volume placed between the tips of the mitral
leaﬂets. Similarly, pulsed-wave tissue Doppler was used to
estimate peak early diastolic tissue velocities in the annular
septum and lateral wall (septal and lateral e0, respectively).
Gain settings were optimized to reduce spectral broadening.
The E/e0 ratio, with e0 being an average value from the septal
and lateral aspects of the mitral annulus, was calculated toapproximate LV ﬁlling pressure, which was considered to be
increased if E/e0 >13 (13,14). The values of the E/e0 ratio
were averaged from 3 consecutive cardiac cycles.
Myocardial deformation was evaluated using a semi-
automated 2-dimensional speckle-tracking technique (Echo-
PAC, GE Medical Systems, Milwaukee, Wisconsin) from
the 3 apical views with typical temporal resolution of
60 frames/s. After initial tracing of the endocardial border and
subsequent software processing, the operator conﬁrmed
adequate tissue tracking. Segments that could not be tracked
were subjected to manual readjustments of the region of
interest, and if this was unsuccessful, they were excluded from
the analysis.The parameters (peak strain, deﬁned as the greatest
negative value on the strain curve, and peak systolic strain rate)
were calculated from the entire myocardial region of interest.
Exercise testing. Symptom-limited exercise testing was
performed on a treadmill using a modiﬁed Bruce protocol and
with standard cardiopulmonary stress equipment. Ventilation,
oxygen uptake (VO2), and carbon dioxide production were
monitored continuously, and peak VO2 was calculated as the
average oxygen consumption during the last 30 s of exercise.
Table 1
Clinical and Demographic Characteristics of the
Study Population
Ivabradine
(n ¼ 30)
Placebo
(n ¼ 31) p Value
Age, yrs 66.5  8.5 68.0  8.7 0.49
Women 23 (77) 27 (87) 0.30
BMI, kg/m2 30.3  4.0 29.1  4.4 0.25
HTN 27 (90) 24 (77) 0.19
DM 12 (40) 10 (32) 0.53
LV diastolic dysfunction
grade  II
8 (27) 10 (32) 0.63
Hemoglobin, g/dl 13.4  1.2 13.3  0.9 0.70
Creatinine, mg/dl 0.99  0.22 0.94  0.13 0.20
Pharmacological treatment
ACE inhibitors/ARBs 29 (97) 30 (97) 0.99
Beta-blockers 17 (57) 16 (52) 0.69
Calcium blockers 11 (37) 12 (39) 0.87
Thiazide diuretic agents 13 (43) 11 (35) 0.53
Loop diuretic agents 10 (33) 10 (32) 0.93
Oral hypoglycemic agents 12 (40) 9 (29) 0.37
Values are mean  SD or n (%).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin II receptor blocker; BMI ¼ body mass
index; DM ¼ diabetes mellitus; HTN ¼ arterial hypertension; LV ¼ left ventricular.
JACC Vol. 62, No. 15, 2013 Kosmala et al.
October 8, 2013:1330–8 Ivabradine and Exercise Capacity in HFpEF
1333Echocardiographic evaluation of wall motion, myocardial
deformation, and diastolic function with the assessment
of E/e0 ratio was undertaken before initiation and imm-
ediately after termination of the test. Transmitral ﬂow
and tissue velocities were measured after the acquisition of
2-dimensional imaging loops. In the event of fusion of early
and late diastolic Doppler signals (E and A and/or e0 and a0)
at high heart rates, images were acquired at the earliest
time point when separation of the E and A waves was
discernible.
To assess the progression of increment in heart rate in
the context of different exercise capacity during the post-
treatment exercise test, we derived the work load–corrected
chronotropic response (WCCR). This was calculated from
the difference in heart rate between the baseline and follow-
up tests at the same exercise time. This time was deﬁned by
test completion in the test with the lower exercise time. For
example, in patients with increases in exercise duration at
follow-up, we used the exercise time at the baseline test, so
WCCR was the maximal heart rate on the baseline test
minus the intermediate heart rate on a follow-up test at the
comparable time point. In patients with decreases in exercise
duration at follow-up, we used the exercise time on the
follow-up test, so WCCR was an intermediate heart rate on
a baseline test at the time point compatible with the exercise
time on a follow-up test minus the maximal heart rate on the
follow-up test.
BNP measurement. Peripheral venous blood samples were
drawn between 8 and 9 AM after a 30-min rest in the supine
position. Plasma samples were frozen at 70C until assay.
BNP level was quantiﬁed using a commercially available
ﬂuorescence immunoassay (Triage BNP Test, Biosite Di-
agnostics, Inc., San Diego, California).
Endpoints. The primary endpoints were changes in exer-
cise capacity as assessed by peak VO2 and post-exercise LV
ﬁlling pressure (E/e0). Secondary endpoints included alter-
ations in myocardial deformation (2-dimensional strain and
strain rate) and peak e0, representing LV systolic and dia-
stolic function, respectively, and changes in neurohormonal
activation as measured by plasma BNP.
Statistical analysis. The initial sample size was calculated
on the basis of assumption of a standard deviation of 30%
of exercise capacity and a 20% effect size (assuming a sim-
ilar improvement in exercise capacity as that obtained
from nondihydropyridine calcium-channel blockers or beta-
blockers in a recent meta-analysis of treatments for HFpEF
[15]). Subsequent work showed that a 30% to 35% effect
size for exercise capacity in heart failure could be achieved
with ivabradine (mainly systolic heart failure) (17). On the
basis of these assumptions, we planned a study of 31 patients
per group to provide 80% power to show a difference in
exercise tolerance at a 2-sided alpha level of 0.05.
Data are expressed as mean  SD for normally distributed
variables, as median (interquartile range) for skewed vari-
ables (BNP), and as counts and percents for categorical
variables. Between-group comparisons were carried out usingunpaired 2-sided Student t tests for continuous variables and
chi-square tests for categorical variables. Homogeneity of
variances was assessed using the Levene test. Longitudinal
analyses were performed using paired 2-sided Student t tests.
BNP, which was found not to ﬁt a normal distribution, was
analyzed using the Mann-Whitney U test for intergroup and
theWilcoxon test for within-group comparisons. Associations
between variables were studied using Pearson or Spearman
correlation coefﬁcients and stepwise multiple regression anal-
ysis. Variables were put into the stepwise models in order of
descending signiﬁcance in the univariate analyses. Changes in
particular parameters with intervention were calculated by
subtracting the baseline value from the follow-up value and
were expressed in the units of their measurements. The
reproducibility of measurements of E/e0 ratio was evaluated in
20 randomly selected examinations and expressed using
intraclass correlation and Bland-Altman (mean and 95%
conﬁdence interval [CI])methods.All analyseswere performed
using standard statistical software (Statistica for Windows
version 10, StatSoft Inc., Tulsa, Oklahoma). The level of
statistical signiﬁcance was set at a 2-sided p value<0.05, apart
from assessment of the coprimary endpoints, for which Bon-
ferroni correction was applied (p ¼ 0.025).Results
Clinical characteristics. Patient characteristics are dis-
played in Table 1. The study patients had a mean age of
67  8 years, were overweight, and were mostly women. A
history of hypertension and/or type 2 diabetes was common.
At baseline, there were no differences in resting heart rate,
blood pressure, BNP level, and cardiac morphology and
function, nor in cardiac functional reserve and exercise
capacity, between the treatment and placebo groups
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1334(Tables 2 and 3, Fig. 2). Delayed relaxation was diagnosed
in 43 patients and increased ﬁlling pressure in 18 patients.
There were no differences in clinical characteristics between
groups allocated to ivabradine or placebo.
Effects of intervention. All enrollees completed the study.
There were no reported adverse events or need to reduce the
dose or stop the treatment with ivabradine in any participant.
Exercise capacity. Baseline exercise capacity (both esti-
mated metabolic equivalents [METs] based on treadmill
time and measured VO2) was impaired. Figure 2 illustrates
a signiﬁcant increment of exercise capacity in the group
treated with ivabradine, with no change in the control
subjects. Consequently, the change in METs was greater
in the treated patients than controls (1.5  1.2 vs. 0.4 
1.2, p ¼ 0.001), as was the change in peak VO2 (3.0  3.6
ml/kg/min vs. 0.4  2.7 ml/kg/min, p ¼ 0.003). This
change was signiﬁcant after correction for multiple
comparisons. Likewise, changes indicating improvement in
ventilation versus carbon dioxide production slope and peak
oxygen pulse were seen in the ivabradine group (Table 2).
All study subjects achieved peak respiratory exchange ratio
values >1, satisfying the prerequisite for the validity of
attained peak VO2.
Echocardiography. The treatment group showed an
improvement in resting LV lusitropic function, as indicated
by higher septal e0 (Table 2). There was no evidence that
these changes occurred in response to increased pre-load,
because there was no accompanying change in resting E/e0Table 2
Resting Heart Rate, Blood Pressure, BNP, Cardiopulmonary
of the Study Population
Ivabradine (n ¼ 30)
Baseline Follow-Up p Value
Heart rate, beats/min 72  7 62  8 0.001
Systolic BP, mm Hg 130  18 130  15 0.91
Diastolic BP, mm Hg 75  8 74  8 0.90
BNP, pg/ml 42 (18–104) 46 (21–108) 0.85
Heart rate at post-exercise
E/e0 recording, beats/min
96  8 97  10 0.49
Peak RER 1.07  0.06 1.08  0.07 0.39
VE/VCO2 31.0  8.3 27.7  4.9 0.01
Peak oxygen pulse, ml/beat 9.3  4.2 12.1  3.5 0.004
LV end-diastolic diameter, mm 48  6 48  5 0.86
Septal wall, mm 12  2 12  2 0.55
Posterior wall, mm 10  2 10  1 0.97
LV mass index, g/m2 115  33 118  36 0.95
LA volume, ml/m2 37.2  9.0 34.9  8.7 0.19
LV ejection fraction, % 67  7 68  6 0.87
Strain, % 19.8  3.0 20.7  3.8 0.17
Strain rate, 1/s 1.12  0.17 1.13  0.24 0.99
E/A ratio 0.91  0.38 1.07  0.38 0.002
E-wave deceleration time, ms 232  54 226  43 0.74
E/e0 13.5  3.2 14.2  3.0 0.40
Septal velocity (e0), cm/s 5.4  1.1 6.1  1.3 0.007
Lateral velocity (e0), cm/s 7.6  1.7 8.1  1.8 0.18
Values are mean  SD or median (interquartile range).
A ¼ late diastolic mitral ﬂow velocity; BNP ¼ brain natriuretic peptide; BP ¼ blood pressure; D ¼ change
e0 ¼ peak early diastolic mitral annular velocity; LA ¼ left atrial; LV ¼ left ventricular; RER ¼ respiratoror circulating BNP (Table 2). In post hoc analyses, this
effect was shown only in patients with grade I diastolic
dysfunction (E/A ratio 0.75  0.12 at baseline vs. 0.94 
0.26 at follow-up, p ¼ 0.01, and septal e0 5.2  1.1 cm/s at
baseline vs. 6.0  1.4 cm/s at follow-up, p ¼ 0.004), but not
in patients with grade  II diastolic dysfunction (E/A ratio
1.42  0.50 at baseline vs. 1.50  0.43 at follow-up,
p ¼ 0.83, and septal e0 6.0  1.2 cm/s at baseline vs. 6.2
 1.0 cm/s at follow-up, p ¼ 0.61). Although there was no
change in resting E/e0 ratio, the treatment group demon-
strated a reduction in exercise-induced increase in E/e0 ratio,
suggesting an improvement in changes in LV ﬁlling pressure
induced by exertion (Table 3).
There were no changes in resting values or functional
reserve for systolic function or myocardial deformation
(strain, strain rate, and LV ejection fraction) (Tables 2
and 3).
Hemodynamics. There was a decrease in resting heart rate
in the treatment group. The absence of change in the
response of this parameter to exercise (Tables 2 and 3) may
have reﬂected differences in exercise performance. WCCR
(the difference in heart rate at the same exercise time on the
baseline and follow-up tests) showed a slower increase in
heart rate during exercise than in the placebo-treated group
(Fig. 3).
There were no signiﬁcant changes in other resting values
or functional reserve markers at follow-up compared with
baseline in the placebo group (Tables 2 and 3).Exercise Testing, and Myocardial Characteristics
Placebo (n ¼ 31)
p for D Ivabradine
vs. D PlaceboBaseline Follow-Up p Value
70  6 70  7 0.98 0.001
133  17 132  15 0.76 0.63
76  7 76  7 0.95 0.44
62 (28–140) 67 (36–115) 0.51 0.51
96  7 99  9 0.20 0.54
1.08  0.06 1.07  0.06 0.51 0.33
31.4  6.1 30.9  5.8 0.71 0.04
8.1  3.8 8.5  3.8 0.57 0.008
46  5 47  4 0.45 0.62
12  2 12  2 0.77 0.80
10  2 10  2 0.97 0.54
113  32 115  35 0.73 0.72
36.3  9.3 35.5  8.6 0.73 0.43
69  6 68  5 0.98 0.43
20.8  3.7 21.0  2.6 0.94 0.29
1.20  0.17 1.21  0.21 0.99 0.95
1.02  0.57 1.01  0.55 0.99 0.004
236  60 232  52 0.89 0.65
14.3  3.1 14.3  3.3 0.99 0.23
5.4  1.2 5.4  1.2 0.86 0.01
7.2  1.7 7.0  2.0 0.55 0.16
during follow-up (follow-up value minus baseline value); E ¼ peak early diastolic mitral ﬂow velocity;
y exchange ratio; VE/VCO2 ¼ ventilation versus carbon dioxide production slope.
Table 3 Myocardial and Hemodynamic Reserve (Exercise Increment) at Baseline and After Treatment in the Study Population
Exercise Increment*
Ivabradine (n ¼ 30) Placebo (n ¼ 31)
p for D Ivabradine
vs. D PlaceboBaseline Follow-Up p Value Baseline Follow-Up p Value
E/A ratio 0.30  0.37 0.31  0.29 0.99 0.33  0.35 0.21  0.29 0.07 0.06
E-wave deceleration time, ms 56  39 44  32 0.40 55  39 55  37 0.99 0.26
E/e0 3.1  2.7 1.3  2.0 0.004 3.5  3.0 2.8  1.9 0.31 0.11
Septal velocity (e0), cm/s 1.1  0.9 1.8  1.1 0.03 1.0  0.8 1.4  1.2 0.18 0.59
Lateral velocity (e0), cm/s 1.2  1.1 2.0  1.6 0.18 1.1  1.4 1.8  1.4 0.24 0.96
Strain, % 1.8  2.0 1.6  1.5 0.96 1.7  1.1 1.6  1.3 0.98 0.85
Strain rate, (1/s) 0.18  0.17 0.22  0.11 0.85 0.21  0.19 0.19  0.15 0.98 0.43
LV ejection fraction, % 6  5 5  5 0.80 7  5 7  5 0.98 0.66
Heart rate, beats/min 46  16 52  17 0.21 49  20 49  17 0.98 0.27
Systolic BP, mm Hg 34  19 37  15 0.89 32  18 35  19 0.90 0.98
Diastolic BP, mm Hg 1  11 1  12 0.95 1  10 1  9 0.97 0.90
Values are mean  SD. *Increase from rest to exercise (exercise value minus resting value).
Abbreviations as in Table 2.
Figure 2
Exercise Capacity in the Study Population at
Baseline and Follow-Up
There were no differences in baseline metabolic equivalents (METs) or peak
oxygen uptake (VO2) between the ivabradine and placebo groups, but follow-up
METs (p ¼ 0.02) and peak VO2 (p ¼ 0.005) were greater with ivabradine. This
reﬂected signiﬁcant increments of both METs (p¼ 0.001) and peak VO2 (p¼ 0.001)
with ivabradine therapy but none with placebo.
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1335Diastolic dysfunction and heart rate subanalyses. The
effect of heart rate slowing may be different in patients with
grade I and grade II diastolic dysfunction, on the basis of
potential beneﬁts of prolonging LV ﬁlling in the former
and heart rate dependence of cardiac output in the latter.
However, no differences between these subgroups of
patients were found in baseline or follow-up BNP, METs,
peak VO2, and exercise increment of E/e0 ratio (Online
Table 1). Similarly, subdivision according to resting heart
rate subgroups of >70 and 70 beats/min, as well as with
normal and reduced chronotropic response to exercise (a
failure to achieve 80% of the maximum age-predicted peak
heart rate) were similar (Online Tables 2 and 3). Likewise,
there were no differences in exercise and hemodynamic
responses to treatment or placebo in groups below and at or
above the median stroke volume (Online Table 4).Figure 3 Work Load–Corrected Chronotropic Response
Work load–corrected chronotropic response (WCCR) is based on the difference in
heart rate between the baseline and follow-up tests at the same exercise time. The
ﬁgure shows that at the same work load, the heart rates of most ivabradine-treated
patients were 10 beats/min less than those of placebo-treated patients.
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1336Determinants of improvements in exercise capacity and
response of E/e0 ratio to exercise. The independent cor-
relates of changes in exercise capacity and diastolic physi-
ology were assessed by modeling combinations of covariates.
These included resting and maximal exercise heart rate and
blood pressure, body mass index, LV mass index, baseline
METs (for DMETs), background treatment with beta-
blockers, and, for DMETs and D peak VO2, change with
treatment in exertional increases in LV ejection fraction and
strain. Therapy with ivabradine was independently associ-
ated with improvement in exercise capacity, as indicated by
increases in METs and peak VO2 (Table 4). Other inde-
pendent associations were WCCR, change with treatment
in exertional increase in E/e0 ratio, age, and baseline peak
VO2 (for D peak VO2). Improvement of LV ﬁlling pressure
estimated by E/e0 ratio was independently associated with
ivabradine treatment (b ¼ 0.24), as well as the baseline
value of exertional increase in E/e0 ratio (Table 4). The use
of beta-blockers was not a signiﬁcant correlate, either
univariate or multivariate, of changes in exercise capacity and
LV ﬁlling pressure.
Reproducibility. The level of agreement in measurements of
E/e0 ratio between both centers participating in this trial was
high, as suggested by the intraclass correlation coefﬁcients
(ICCs) and mean differences: ICC ¼ 0.93 (p < 0.001)
and 0.4 (95% CI: 1.5 to 0.7) at rest and ICC ¼ 0.92
(p < 0.001) and 0.2 (95% CI: 1.0 to 0.6) at exercise. Intra-
observer and interobserver variability of E/e0 ratio were as
follows: at the Polish center, ICC ¼ 0.96 (p < 0.001) and 0.5
(95%CI:0.0 to1.0) and ICC¼ 0.96 (p< 0.001) and0.2 (95%
CI:0.6 to 0.2) at rest and ICC¼ 0.94 (p< 0.001) and0.3
(95%CI:1.0 to0.3) and ICC¼ 0.97 (p< 0.001) and0.7 (95%
CI: 0.2 to 1.2) during exercise; at the Australian center, ICC¼
0.99 (p< 0.001) and 0.0 (95%CI:0.3 to 0.3) and ICC¼ 0.93
(p < 0.001) and 0.3 (95% CI: 0.4 to 1.0) at rest and ICC ¼
0.97 (p< 0.001) and 0.0 (95%CI:0.3 to 0.3) and ICC¼ 0.98
(p < 0.001) and0.1 (95% CI: 0.7 to 0.4) during exercise.Discussion
This randomized, placebo-controlled study demonstrated
that short-term treatment with ivabradine improves exerciseTable 4 Multivariate Predictors of Improvements in Exercise Capaci
DMETs
(R2 ¼ 0.40)
b SE p Value
WCCR 0.42 0.14 0.005
Change in exercise increment of E/e0 0.30 0.13 0.02
Ivabradine therapy 0.34 0.16 0.04
Age 0.20 0.13 0.14
Peak VO2 at baseline
ExI E/e0 at baseline
LVMI
ExI ¼ increase from rest to exercise (exercise value minus resting value); LVMI ¼ left ventricular mass in
response; other abbreviations as in Table 2.capacity in patients with HFpEF. This coincided with
a reduction of the exercise-induced increase in LV ﬁlling
pressure (E/e0 ratio). These ﬁndings in carefully selected
patients with reduced exercise capacity, exercise-induced
diastolic dysfunction, and low resting BNP levels support
further investigations of ivabradine in larger and longer
duration clinical trials in patients with HFpEF.
Diastolic evaluation. Exertional dyspnea is a nonspeciﬁc
symptom, and concern is often expressed over the frequency of
diastolic dysfunction leading to the overdiagnosis of HFpEF.
The present study was performed in a carefully selected group
of symptomatic, functionally impaired patients with HFpEF
after the exclusion of other plausible causes of shortness of
breath, such as lung disease or anemia. The lack of speciﬁcity of
diastolic abnormalities as the reason for exercise intolerance is
a limitation of previous investigations in HFpEF. We sought
to avoid this in this study by performing the evaluation during
exercise, which allowed us to relate symptomatic status to
exercise changes in hemodynamic status.
Delayed relaxation represents the early process associated
with diastolic dysfunction, which is followed by LV stiff-
ening, both exerting deleterious effects on diastolic ﬁlling
(18,19). Importantly, signiﬁcant slowing of LV relaxation
may result in elevation of both early and, to a lesser extent,
late diastolic pressure, regardless of coexisting abnormalities
of myocardial compliance (19). Despite near normal LV
ﬁlling pressure values at rest in some patients, elevation of
LV ﬁlling pressure on exertion is associated with exertional
dyspnea (20–22). Patients with increments of E/e0 ratio with
exercise were selected to make the group more speciﬁc for
cardiac dyspnea (15,23–25).
A number of mechanisms may explain the favorable effect
of ivabradine in HFpEF. In patients with delayed relaxation,
lengthening of diastolic ﬁlling time may permit more
complete LV ﬁlling. Patients with HFpEF have inappro-
priate tachycardia during exercise, with higher heart rates at
constant work loads than in subjects with normal LV ﬁlling
(20,26), on the basis of impaired stroke volume reserve and
reliance on increasing heart rate to augment cardiac output.
Interestingly, patients with increased LV ﬁlling pressure or
the absence of resting tachycardia were no less likely to
respond to ivabradine (Online Tables 1 and 2).ty and Response of E/e0 Ratio to Exercise in the Study Population
D Peak Vo2
(R2 ¼ 0.58)
D ExI E/e0
(R2 ¼ 0.62)
b SE p Value b SE p Value
0.15 0.11 0.20
0.32 0.11 0.007 0.24 0.08 0.006
0.35 0.11 0.003
0.68 0.11 0.001
0.81 0.09 0.001
0.12 0.08 0.18
dex; MET ¼ metabolic equivalent; VO2 ¼ oxygen uptake; WCCR ¼ work load–corrected chronotropic
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1337As demonstrated in animal models, the mechanisms
behind the favorable effect of ivabradine on LV diastolic
function are not conﬁned to a simple lengthening of diastolic
ﬁlling time. Other beneﬁts include acceleration of myocar-
dial relaxation by enhancing the phosphorylation of phosp-
holamban and subsequent stimulation of sarcoplasmic
reticulum Ca2þ adenosine triphosphatase, increase in my-
ocardial compliance by reducing the expression of the titin
N2B isoform and myocardial collagen content, and imp-
rovement of arterial stiffness and endothelial function
(6,8,27). Clearly, some of these mechanisms require a longer
treatment duration to be effective.
As evidenced in our analysis, the improvement of exercise
capacity with ivabradine was associated with a slower
increase in heart rate during exercise (as expressed by
WCCR). This may have been paralleled by a slower exer-
tional increase in LV ﬁlling pressure with delayed onset of
dyspnea and exercise termination. Indeed, some patients
might have developed similar levels of LV ﬁlling pressures as
in the pre-treatment period but at a later stage of exercise.
Unfortunately, noninvasive estimation of LV ﬁlling pressure
during exercise (in contrast to post-exercise measurements in
our protocol) using the E/e0 ratio is difﬁcult because of the
fusion of the E and A waves of the mitral inﬂow and annular
e0 and a0 waves at high heart rates. These considerations may
explain the lack of post-treatment reduction in exercise-
induced increase in E/e0 ratio between treatment and
control.
We did not demonstrate signiﬁcant differences in bene-
ﬁcial effect of ivabradine on exercise tolerance between
patients with grade I and grade II diastolic dysfunction,
but this ﬁnding needs to be veriﬁed in larger patient
populations.
Heart rate control and heart failure. Although the heart
failure guidelines mention a possible use of heart rate–
slowing drugs (especially beta-blockers) for alleviating heart
failure symptoms in patients with HFpEF (3,4), the role of
therapeutic bradycardia in this population is controversial.
Previous studies showed inconsistent results concerning
effects of beta-blockade on LV diastolic function and exer-
cise tolerance in patients with HFpEF (28–33). Notably,
heart rate control attained with beta-receptor antagonists is
accompanied by the negative inotropic and lusitropic effects
of this class of drugs. Apart from this, beta-blockade may
directly increase cardiomyocytes stiffness (34). Compared
with atenolol, ivabradine lacks a negative lusitropic effect
at similar levels of heart rate reduction (10) and provides
similar decreases in myocardial oxygen demand without
detrimentally affecting LV contractility (35,36). Finally,
traditional beta-blockade may contribute to increased central
systolic loading, despite lowering brachial blood pressure
(37). This effect may be detrimental to central hemodynamic
status in HFpEF, especially on exertion, and substitution of
this drug class with ivabradine may be particularly useful.
Indeed, apart from the beneﬁcial changes during exercise,
ivabradine therapy was associated with a positive lusitropiceffect at rest in patients with HFpEF with grade I diastolic
dysfunction, as indicated by higher septal e0 and mitral E/A
ratio. This ﬁnding is in line with prior experimental studies
(6,7,9,10).
Study limitations. First, BNP was ineffective in tracking
clinical and hemodynamic improvements in this study. This
reﬂects challenges in applying BNP in this population,
especially in the context of their mean body mass index of 30
kg/m2 (38). Additionally, we measured this marker only at
rest, not during exercise, when the favorable effect of ivab-
radine on LV ﬁlling pressure was observed.
Second, the improvement in exercise capacity after a short
duration of treatment represents the acute effect of therapy
on hemodynamic status. Long-term treatment may permit
patients with HFpEF to engage in greater levels of physical
activity, further improving functional capacity.
Third, we studied the effects of ivabradine on maximal
exercise performance and cannot extrapolate our data to the
effects of the drugon submaximal exercise hemodynamic status.
Fourth, we did not evaluate the effect of ivabradine on
arterial function, especially in the context of its potential
impact on exercise tolerance.
Fifth, there is a dose-response effect of ivabradine on
heart rate reduction (39). In this study, we examined the
effects of a ﬁxed dose of ivabradine (5 mg), which is effective
for rate reduction, but we did not titrate the drug to reach
speciﬁc heart rate thresholds.
Finally, the limited sample size precluded testing inter-
actions with treatment groups in the multivariate regression
model.
Conclusions
Ivabradine therapy is an effective therapy to increase exercise
tolerance in patients with HFpEF. This beneﬁcial effect is
potentially mediated by the improved LV ﬁlling pressure
response to exercise. Because patients with HFpEF are often
symptomatic only on exertion, treatments targeting abnormal
exercise hemodynamic status may prove useful.
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